The PennZone

  • Home
  • Non-profit
  • Technology
  • Entertainment
  • Business
  • Education
  • Marketing
  • Health
  • Construction

Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client
The PennZone/10216335

Trending...
  • Philadelphia Community Invited to Unite for Praise-A-Thon Summer Concert Benefiting Cobbs Creek
  • Cover Story about Matthew Cossolotto – Author of Harness Your PromisePower -- Published in July 2026 Enterprise World Magazine
  • Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
Beneficience Com Announces Dr John Burd, Renowned Dr John Burd Lysulin© Dr Burd Wonder Spray Skin Rescue 8oz Skin Rescue Lysulin© Products Beneficience.com Legacy PR
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.

SAN DIEGO - PennZone -- About John Burd, PhD:

Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc.  In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes.   The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications.  In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.

Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes.  In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million.  In 2020 DexCom had a market cap of over $40 billion.  From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.

Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market.  LXN was sold to Johnson and Johnson in 2000.

More on The PennZone
  • Crossroads4Hope Announces The Lipschutz Women's Fund
  • AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)
  • 91 Per Cent of Enterprises Will Increase AI Spending. Most Can't See the Cost — or the Risk!
  • Harrisburg's newest restaurant, Eleve, sells out entire inventory during Grand Opening
  • New ProEssentials v11: Native WinUI Charting Library, 100M Points in 15ms, Following Microsoft's Vision for True Native Swap-Chain Rendering

Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance.  MAST Immunosystems was purchased by Hitachi Chemical in 1997.  Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).

Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products.  He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.  In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.

Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

JOHN F. BURD, Ph.D.

Founder & CEO Lysulin, Inc and Wonder Spray, llc.

More on The PennZone
  • New AI Customer Segmentation Guide Warns Marketers Not to Confuse Technical Precision With Business Value
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
  • Aderra Opens in Magnolia, Texas, Offering a New Model for 62+ Homeownership
  • What's New in Hokkaido, Autumn 2026
  • CRG Awarded NASA SEWP VI Contracts in Categories B and C

4930 Bradshaw Court, San Diego, CA  92130
Phone: 619-992-2873

Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)

Learn more about Dr. Burd's products below...

Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8



Lysulin video:  https://www.youtube.com/watch?v=PK3CkMty6RE



Running A1c test: https://tinyurl.com/y379jbla

Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos

Follow Burd's PR News at http://Beneficience.com

MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd

Contact
Dr. Tracey Bond, MPRL
Certified Publicist of Record
for John Burd, PhD
***@beneficience.com


Source: Beneficience.com Legacy PR
Filed Under: Business, Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Lineus Medical Signs Partnership Agreement with DIMA MedTech to Support Expansion into Italy
  • New Research: Deterministic Decompilation of Hermes Bytecode Back to Readable JavaScript
  • The J. Wes Project Celebrates 11 Years of Love, Music & Inspiration
  • Lionheart Holdings and KEO Energy Sign Letter of Intent for Proposed Business Combination
  • MoMojo Records announces new album from Jad Tariq
  • Marcus Christ Announces Singles: "The Hammer Goes Click" and "You Hate Me, I Hate You"
  • Fatal FOMO May be Your Last Roll of the Dice
  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
  • Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio
  • Community Partnership Brings Live Theater to 150+ Young People
  • Best Rainbow Baby Charities That Support Bereaved Parents After Pregnancy Loss: A Complete Guide
  • PokerStars & Ladbrokes veteran buys into Finnish news media Rahapelisanomat
  • Former Judge Chris Oldner Honored as Best Lawyer by "D Magazine" for 6th Straight Year
  • Missouri Hemp Businesses File Federal Lawsuit Challenging HB 2641
  • Boston Industrial Solutions Launches New Citrine® SA1-370 Silicone Glue for Permanent Adhesion
  • Northeast Airlines Launches New Asset Management Group
  • AI Visibility Labs LLC - Dallas Texas - July 16 2026
  • NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
  • ET&T Adds Senior Technical Voice Engineer to Strengthen Local Team
  • Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers

Popular on PennZone

  • Proper Sky Named to the 2026 MSP 501
  • Slotozilla Introduces a Centralized Resource for World Cup Bonus Offers
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • Dentists launch independent platform to help practices choose the right technology
  • 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
  • New "Lakeside Picnic Ride" Package in Japan's Lake Chuzenji region of Nikko: July 1- November 30, 2026
  • RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
  • Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules
  • Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love

Similar on PennZone

  • Crossroads4Hope Announces The Lipschutz Women's Fund
  • AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)
  • Harrisburg's newest restaurant, Eleve, sells out entire inventory during Grand Opening
  • New AI Customer Segmentation Guide Warns Marketers Not to Confuse Technical Precision With Business Value
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
  • Aderra Opens in Magnolia, Texas, Offering a New Model for 62+ Homeownership
  • CRG Awarded NASA SEWP VI Contracts in Categories B and C
  • Elevate Your Sneakers With Crep Protect Trek Laces
  • Meet Privateer: Tucson's High-Tech Security Force Built With Paramilitary Precision
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us